Blanca Farre-Gonzalez - Publications

SAFE-IOERT prospective study: clinical outcomes of exclusive intraoperative radiotherapy in early breast cancer according to molecular subtype and tumor-infiltrating lymphocytes.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 15, 2026

Genomic Architecture of IRF4 Rearrangements in Children and Adult Large B-cell Lymphomas.

Journal: Blood advances

Published: March 20, 2026

Erratum to "Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study": [ESMO Open 9 (2024) 103989].

Journal: ESMO open

Published: January 06, 2026

Molecular effects of ovarian stimulation for fertility preservation in breast cancer: a paired-biopsy analysis.

Journal: ESMO open

Published: December 23, 2025

Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 19, 2025

Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy.

Journal: ESMO open

Published: July 11, 2025

Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial.

Journal: ESMO open

Published: June 05, 2025

Preoperative Radiation Therapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results From the YOUNGSTER trial.

Journal: International journal of radiation oncology, biology, physics

Published: January 30, 2025

Latent representation of H&E images retains biological information in a breast cancer cohort.

Journal: PloS one

Published: July 14, 2024

Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study.

Journal: ESMO open

Published: July 03, 2024

Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 23, 2024

Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer.

Journal: Scientific reports

Published: March 06, 2024